A new trading day began on Tuesday, with Apellis Pharmaceuticals Inc (NASDAQ: APLS) stock price down -2.06% from the previous day of trading, before settling in for the closing price of $24.26. APLS’s price has ranged from $23.77 to $59.91 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 92.54%. Meanwhile, its annual earnings per share averaged 37.94%. With a float of $104.48 million, this company’s outstanding shares have now reached $124.50 million.
Let’s determine the extent of company efficiency that accounts for 710 employees. In terms of profitability, gross margin is 84.82%, operating margin of -21.11%, and the pretax margin is -25.18%.
Apellis Pharmaceuticals Inc (APLS) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Apellis Pharmaceuticals Inc is 16.76%, while institutional ownership is 99.36%. The most recent insider transaction that took place on Mar 17 ’25, was worth 4,543. In this transaction VP/Chief Accounting Officer of this company sold 183 shares at a rate of $24.82, taking the stock ownership to the 47,955 shares. Before that another transaction happened on Mar 17 ’25, when Company’s Officer proposed sale 183 for $24.82, making the entire transaction worth $4,543.
Apellis Pharmaceuticals Inc (APLS) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 37.94% per share during the next fiscal year.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Trading Performance Indicators
Here are Apellis Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.60, a number that is poised to hit -0.34 in the next quarter and is forecasted to reach 0.17 in one year’s time.
Technical Analysis of Apellis Pharmaceuticals Inc (APLS)
Looking closely at Apellis Pharmaceuticals Inc (NASDAQ: APLS), its last 5-days average volume was 2.14 million, which is a jump from its year-to-date volume of 1.75 million. As of the previous 9 days, the stock’s Stochastic %D was 15.83%. Additionally, its Average True Range was 1.08.
During the past 100 days, Apellis Pharmaceuticals Inc’s (APLS) raw stochastic average was set at 3.16%, which indicates a significant decrease from 14.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 28.01% in the past 14 days, which was lower than the 54.09% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $27.34, while its 200-day Moving Average is $32.54. However, in the short run, Apellis Pharmaceuticals Inc’s stock first resistance to watch stands at $24.34. Second resistance stands at $24.91. The third major resistance level sits at $25.40. If the price goes on to break the first support level at $23.28, it is likely to go to the next support level at $22.79. Now, if the price goes above the second support level, the third support stands at $22.22.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Key Stats
With a market capitalization of 2.98 billion, the company has a total of 125,516K Shares Outstanding. Currently, annual sales are 781,370 K while annual income is -197,880 K. The company’s previous quarter sales were 212,530 K while its latest quarter income was -36,350 K.
